What is OPK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.98B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OPK?

P/E (TTM) is n/a and 52-week range is $0.98 to $1.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OPK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OPK?

The company profile lists revenue (TTM) near $861M, net income (TTM) near $-20.60B, EPS (TTM) near $-0.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is OPKO Health Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami, Florida, US, 746.3M shares outstanding, ISIN US68375N1037 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

OPKO Health Inc

$OPK

Health Care · Health Care Providers & Services

IR Run Scenarios

$1.37

+3.79%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Employees

2,275

Website

www.opko.com/

IPO

1995-11-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)